ezetimibe has been researched along with Obesity in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (37.14) | 29.6817 |
| 2010's | 22 (62.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, Y; Chen, YG; Ji, XP; Li, CB; Li, XX; Liu, BS; Xu, F; Zhang, C; Zhao, L | 1 |
| Endo, H; Kanazawa, M; Kondo, M; Nakamura, A; Nozaki, E; Sato, K; Takahashi, T | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J; Vides, H | 1 |
| Adachi, H; Bekki, H; Honma, T; Nakano, H; Nakata, M; Nohara, M; Yamamoto, K; Yoshiyama, H | 1 |
| Drozd, VIu; Haĭdychuk, VS; Khukhlina, OS; Kosar, LIu; Mandryk, OIe | 1 |
| Chang, E; Kim, L; Lee, WY; Oh, KW; Park, CY; Park, SE; Park, SW; Rhee, EJ | 1 |
| Dalbøge, LS; Fabricius, K; Hansen, G; Hansen, HB; Jelsing, J; Pedersen, PJ; Vrang, N | 1 |
| Abd-Ellah, MF; Gad, MA; Helal, GK; Mahgoup, EM | 1 |
| Chung, RT; Corey, KE; Giugliano, R; Simon, TG | 1 |
| Frydrychowicz, C; Mueller, W; Pasieka, B; Petros, S; Pierer, M; Weidhase, L | 1 |
| Lüscher, TF | 1 |
| Gao, X; Jacobs, RL; Kassiri, Z; Lingrell, S; Takawale, A; van der Veen, JN; Vance, DE | 1 |
| Elisaf, MS; Filippatos, TD; Georgoula, M; Kiortsis, DN; Mikhailidis, DP; Nakou, ES; Tselepis, AD | 1 |
| Dallinga-Thie, GM; Hajer, GR; van Vark-van der Zee, LC; Visseren, FL | 1 |
| Camarota, LM; Davies, JP; Gilham, DE; Howles, PN; Hui, DY; Ioannou, YA; Jandacek, RJ; Labonté, ED; Rojas, JC; Tso, P | 1 |
| de Bree, P; Doevendans, PA; Hajer, GR; Hoefer, IE; Olijhoek, JK; Rafii, S; Verhaar, MC; Visseren, FL; Westerweel, PE | 1 |
| Díaz Gómez, JM | 1 |
| Derdemezis, CS; Elisaf, MS; Filippatos, TD; Kiortsis, DN; Mikhailidis, DP; Nakou, ES; Tselepis, AD | 1 |
| Elisaf, M; Florentin, M; Kostapanos, MS; Liberopoulos, EN; Nakou, ES | 1 |
| Derdemezis, CS; Elisaf, M; Florentin, M; Liberopoulos, EN; Tellis, CC; Tselepis, A | 1 |
| Hasegawa, K; Hiramitsu, S; Hishida, H; Ishiguro, Y; Kani, A; Kato, K; Matsubara, Y; Matsuyama, H; Noba, M; Ozaki, Y; Uemura, A; Yamada, K; Yoshida, S | 1 |
| Barrett, PH; Chan, DC; Gan, SK; Ooi, EM; Watts, GF | 1 |
| Enjoji, M; Kato, M; Kohjima, M; Kotoh, K; Machida, K; Matsunaga, K; Nakamuta, M; Nakashima, M | 1 |
| Agouridis, AP; Bairaktari, ET; Elisaf, MS; Filippatos, TD; Kostara, C; Nakou, ES | 1 |
| Cramariuc, D; Gerdts, E; Gohlke-Bärwolf, C; Lund, BP; Rieck, AE; Rossebø, AB | 1 |
| Dong, YF; Fukuda, M; Kataoka, K; Kim-Mitsuyama, S; Nakamura, T; Nako, H; Ogawa, H; Tokutomi, Y; Yasuda, O | 1 |
| Betters, JL; Jia, L; Yu, L | 1 |
| Arai, H; Matsubara, T; Minami, M; Murayama, T; Tamura, Y; Yokode, M | 1 |
| Inazumi, K; Kawakami, C; Kikuchi, K; Koike, H; Miyazaki, T; Nezu, U; Ono, K; Orime, K; Sato, K; Sato, M; Shirakawa, J; Terauchi, Y; Wakasugi, T; Watanabe, S; Yamakawa, T | 1 |
| González-Ortiz, M; Hernández-Salazar, E; Kam-Ramos, AM; Martínez-Abundis, E; Ramos-Zavala, MG | 1 |
| Devaraj, S; Jialal, I | 1 |
| Deushi, M; Haraguchi, M; Ishii, H; Ito, M; Kawakami, A; Nomura, M; Okazaki, M; Yoshida, M | 1 |
| Cook, J; Davis, H; Hoos, L; Hwa, JJ; Tetzloff, G; van Heek, M; Zheng, S | 1 |
| Dallinga-Thie, GM; Hajer, GR; Olijhoek, JK; van Vark-van der Zee, LC; Visseren, FL | 1 |
| Austin, TM; Cook, JA; Davis, HR; Farley, C; Tetzloff, GG; van Heek, M | 1 |
3 review(s) available for ezetimibe and Obesity
| Article | Year |
|---|---|
Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.
Topics: Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Dyslipidemias; Endothelium, Vascular; Ezetimibe; Humans; Inflammation; Insulin Resistance; Intra-Abdominal Fat; Liver; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Obesity, Abdominal; Risk Reduction Behavior; Thrombophilia | 2016 |
[Cardiovascular mortality in kidney transplatation].
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Comorbidity; Coronary Angiography; Diabetes Mellitus; Dyslipidemias; Ezetimibe; Humans; Kidney Diseases; Kidney Transplantation; Myocardial Ischemia; Obesity; Postoperative Complications; Preoperative Care; Prognosis; Risk Factors | 2008 |
Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Azetidines; Biliary Tract; Biological Transport; Carrier Proteins; Cholesterol; Endocytosis; Ezetimibe; Fatty Liver; Humans; Intestinal Absorption; Intestinal Mucosa; Intestines; Liver; Membrane Proteins; Membrane Transport Proteins; Mice; Obesity; Phytosterols; Primates | 2011 |
16 trial(s) available for ezetimibe and Obesity
| Article | Year |
|---|---|
Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Obesity; Peptide Fragments; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
Ezetimibe ameliorates atherogenic lipids profiles, insulin resistance and hepatocyte growth factor in obese patients with hypercholesterolemia.
Topics: Atherosclerosis; Biomarkers; Drug Therapy, Combination; Ezetimibe; Female; Hepatocyte Growth Factor; Humans; Hypercholesterolemia; Insulin Resistance; Lipids; Male; Middle Aged; Obesity | 2015 |
Coadministration of ezetimibe with pegylated interferon plus ribavirin could improve early virological response in chronic hepatitis C obese Egyptian patients.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Egypt; Ezetimibe; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Obesity; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Single-Blind Method; Time Factors; Treatment Outcome; Viral Load; Virus Internalization | 2016 |
The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Anti-Obesity Agents; Anticholesteremic Agents; Azetidines; Body Mass Index; Caloric Restriction; Cholesterol, LDL; Diet, Fat-Restricted; Drug Therapy, Combination; Ezetimibe; Female; gamma-Glutamyltransferase; Homeostasis; Humans; Hypercholesterolemia; Lactones; Male; Middle Aged; Obesity; Orlistat; Overweight; Treatment Outcome; Uric Acid | 2008 |
The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients.
Topics: Adolescent; Adult; Aged; Azetidines; Cross-Over Studies; Double-Blind Method; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins; Male; Metabolic Syndrome; Middle Aged; Obesity; Postprandial Period; Simvastatin | 2009 |
Endothelial progenitor cell levels in obese men with the metabolic syndrome and the effect of simvastatin monotherapy vs. simvastatin/ezetimibe combination therapy.
Topics: Anticholesteremic Agents; Azetidines; Cross-Over Studies; Drug Therapy, Combination; Endothelial Cells; Endothelium, Vascular; Ezetimibe; Humans; Male; Metabolic Syndrome; Middle Aged; Obesity; Postprandial Period; Simvastatin; Stem Cells | 2008 |
The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia.
Topics: Adult; Anti-Obesity Agents; Anticholesteremic Agents; Aryldialkylphosphatase; Azetidines; Body Mass Index; Cholesterol, HDL; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hyperlipidemias; Lactones; Linear Models; Lipoproteins, HDL2; Lipoproteins, HDL3; Male; Middle Aged; Obesity; Orlistat; Phospholipases A2; Time Factors; Treatment Outcome | 2008 |
Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia.
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Azetidines; Body Weight; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Male; Middle Aged; Obesity; Orlistat; Overweight; Piperidines; Pyrazoles; Rimonabant | 2009 |
Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study.
Topics: Adipokines; Adult; Aged; Azetidines; Body Mass Index; Diet, Reducing; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Obesity; Piperidines; Pyrazoles; Rimonabant; Weight Loss | 2010 |
The effects of ezetimibe on surrogate markers of cholesterol absorption and synthesis in Japanese patients with dyslipidemia.
Topics: Aged; Anticholesteremic Agents; Asian People; Azetidines; Biomarkers; Blood Glucose; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Male; Middle Aged; Obesity; Risk Factors; Triglycerides | 2010 |
Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet.
Topics: Adipokines; Aged; alpha-2-HS-Glycoprotein; Anticholesteremic Agents; Apolipoprotein B-100; Azetidines; Biomarkers; Blood Proteins; Body Composition; C-Reactive Protein; Combined Modality Therapy; Diet, Reducing; Ezetimibe; Fatty Liver; Humans; Insulin Resistance; Liver; Middle Aged; Obesity; Patient Compliance; Triglycerides; Weight Loss | 2010 |
The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients.
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Apolipoprotein C-II; Apolipoprotein C-III; Azetidines; Diet, Fat-Restricted; Drug Therapy, Combination; Ezetimibe; Female; Humans; Lactones; Male; Middle Aged; Obesity; Orlistat; Triglycerides | 2010 |
Effect of obesity on left ventricular mass and systolic function in patients with asymptomatic aortic stenosis (a Simvastatin Ezetimibe in Aortic Stenosis [SEAS] substudy).
Topics: Aged; Aged, 80 and over; Angiography; Aortic Valve Stenosis; Azetidines; Body Mass Index; Double-Blind Method; Drug Therapy, Combination; Echocardiography, Doppler; Ezetimibe; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Logistic Models; Male; Middle Aged; Multivariate Analysis; Obesity; Probability; Prognosis; Risk Assessment; Severity of Illness Index; Simvastatin; Stroke Volume; Systole; Treatment Outcome | 2010 |
Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia.
Topics: Adult; Anticholesteremic Agents; Apolipoprotein B-48; Azetidines; Blood Glucose; Cholesterol; Cross-Over Studies; Double-Blind Method; Ezetimibe; Glucose; Humans; Hyperglycemia; Hyperlipidemias; Intestinal Mucosa; Lipid Metabolism; Male; Membrane Proteins; Membrane Transport Proteins; Middle Aged; Obesity; Placebos; Postprandial Period; Prospective Studies; Time Factors; Triglycerides | 2012 |
Effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients.
Topics: Administration, Oral; Adolescent; Adult; Anticholesteremic Agents; Azetidines; Blood Glucose; Blood Pressure Determination; Body Mass Index; Cholesterol; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Ezetimibe; Female; Humans; Insulin Resistance; Lipids; Male; Middle Aged; Obesity; Time Factors; Treatment Outcome | 2006 |
Lipid-lowering therapy does not affect the postprandial drop in high density lipoprotein-cholesterol (HDL-c) plasma levels in obese men with metabolic syndrome: a randomized double blind crossover trial.
Topics: Adolescent; Adult; Aged; Azetidines; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cross-Over Studies; Dietary Fats; Double-Blind Method; Drug Combinations; Ezetimibe; Fasting; Humans; Male; Metabolic Syndrome; Middle Aged; Obesity; Postprandial Period; Simvastatin | 2008 |
16 other study(ies) available for ezetimibe and Obesity
| Article | Year |
|---|---|
Ezetimibe prevents myocardial remodeling in an obese rat model by inhibiting inflammation.
Topics: Animals; Anticholesteremic Agents; Blotting, Western; C-Reactive Protein; Cardiomegaly; Collagen; Diet, High-Fat; Ezetimibe; Heart; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-6; Male; Myocardium; Obesity; p38 Mitogen-Activated Protein Kinases; Rats, Sprague-Dawley; Vascular Cell Adhesion Molecule-1; Ventricular Remodeling | 2018 |
Impact of decreased insulin resistance by ezetimibe on postprandial lipid profiles and endothelial functions in obese, non-diabetic-metabolic syndrome patients with coronary artery disease.
Topics: Aged; Blood Glucose; Coronary Artery Disease; Diabetes Mellitus; Ezetimibe; Female; Humans; Hyperlipidemias; Insulin; Insulin Resistance; Linear Models; Male; Metabolic Syndrome; Middle Aged; Obesity; Postprandial Period; Prospective Studies; Triglycerides | 2019 |
[The use of complex tools ezetimibe, hepadyfu fosinopril and correction of blood pressure and endothelial dysfunction in patients with nonalcoholic steatohepatitis and essential hypertension stage II].
Topics: Adenine; Anticholesteremic Agents; Azetidines; Carnitine; Drug Combinations; Endothelium, Vascular; Essential Hypertension; Ezetimibe; Fosinopril; Humans; Hypertension; Non-alcoholic Fatty Liver Disease; Obesity; Vascular Diseases | 2014 |
Ezetimibe improves hepatic steatosis in relation to autophagy in obese and diabetic rats.
Topics: Animals; Anticholesteremic Agents; Autophagy; Biomarkers; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Type 2; Disease Models, Animal; Ezetimibe; Fatty Liver; Gene Expression Regulation; Hepatocytes; Lipids; Liver; Macrolides; Male; Obesity; Palmitic Acid; Rats, Inbred OLETF; RNA, Messenger | 2015 |
A Hamster Model of Diet-Induced Obesity for Preclinical Evaluation of Anti-Obesity, Anti-Diabetic and Lipid Modulating Agents.
Topics: Animals; Anti-Obesity Agents; Anticholesteremic Agents; Blood Glucose; Cholesterol; Cricetinae; Diet, High-Fat; Eating; Ezetimibe; Hypoglycemic Agents; Hypolipidemic Agents; Linagliptin; Male; Mesocricetus; Neuropeptides; Obesity; Peptide Fragments; Peptide YY | 2015 |
Colchicine triggered severe rhabdomyolysis after long-term low-dose simvastatin therapy: a case report.
Topics: Acute Kidney Injury; Aged; Colchicine; Ezetimibe; Gout Suppressants; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Obesity; Rhabdomyolysis; Simvastatin; Treatment Outcome | 2017 |
Updates on prevention: obesity, ezetimibe, PCSK9, and HIV infection.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Body Mass Index; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Obesity; PCSK9 Inhibitors; Testosterone | 2016 |
Fenofibrate, but not ezetimibe, prevents fatty liver disease in mice lacking phosphatidylethanolamine
Topics: Animals; Disease Models, Animal; Endoplasmic Reticulum Stress; Ezetimibe; Fenofibrate; Humans; Insulin Resistance; Lipid Metabolism; Lipoproteins, VLDL; Liver; Mice; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Obesity; Oxidation-Reduction; Phosphatidylethanolamine N-Methyltransferase; Triglycerides | 2017 |
Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1-/- mice.
Topics: Animals; Azetidines; Diabetes Mellitus; Dietary Carbohydrates; Dietary Fats; Ezetimibe; Fatty Acid Transport Proteins; Fatty Acids; Female; Hyperglycemia; Intestinal Absorption; Male; Membrane Transport Proteins; Mice; Obesity | 2008 |
NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease.
Topics: Adipokines; Adult; Anticholesteremic Agents; Azetidines; Carbohydrates; Cholesterol; Ezetimibe; Fatty Liver; Female; Humans; Liver; Male; Membrane Proteins; Membrane Transport Proteins; Middle Aged; Obesity; Ursodeoxycholic Acid | 2010 |
Ezetimibe ameliorates cardiovascular complications and hepatic steatosis in obese and type 2 diabetic db/db mice.
Topics: Animals; Anticholesteremic Agents; Azetidines; Blood Pressure; Blood Vessels; Body Composition; Body Weight; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Ezetimibe; Fatty Liver; Glucose Tolerance Test; Immunohistochemistry; In Vitro Techniques; Insulin Resistance; Liver; Male; Mice; Mice, Inbred C57BL; Myocardium; NADPH Oxidases; Obesity; Superoxides; Triglycerides | 2010 |
Ezetimibe ameliorates early diabetic nephropathy in db/db mice.
Topics: Adiponectin; Adiposity; Animals; Anticholesteremic Agents; Azetidines; Blood Pressure; Blotting, Western; Body Weight; Creatinine; Diabetic Nephropathies; Ezetimibe; Glomerular Filtration Rate; Inflammation; Kidney Function Tests; Lipid Metabolism; Male; Metabolism, Inborn Errors; Mice; Mice, Obese; Obesity; Oxidative Stress; Real-Time Polymerase Chain Reaction; Receptors, Adiponectin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2012 |
Therapy and clinical trials.
Topics: Acquired Immunodeficiency Syndrome; Atherosclerosis; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Ezetimibe; Humans; Hypercholesterolemia; Metabolic Syndrome; Models, Biological; Obesity; Risk Factors | 2007 |
Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.
Topics: Animals; Anticholesteremic Agents; Azetidines; Blood Glucose; Body Weight; Cells, Cultured; Disease Models, Animal; Dyslipidemias; Ezetimibe; Fatty Liver; Hepatocytes; Insulin Resistance; Lipids; Metabolic Syndrome; Obesity; Rats; Rats, Zucker; Time Factors | 2007 |
Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.
Topics: Alanine Transaminase; Animals; Anticholesteremic Agents; Azetidines; Cholesterol Esters; Cholesterol, Dietary; Dietary Fats; Disease Models, Animal; Dose-Response Relationship, Drug; Ezetimibe; Fatty Liver; Hepatomegaly; Liver; Liver Cirrhosis; Mice; Mice, Inbred C57BL; Obesity; Time Factors; Triglycerides | 2008 |
Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol Esters; Cholesterol, HDL; Cholesterol, LDL; Cricetinae; Ezetimibe; Hypercholesterolemia; Hyperinsulinism; Hyperlipidemias; Hypertriglyceridemia; Liver; Mesocricetus; Obesity; Triglycerides | 2001 |